Business Wire

Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM

24.7.2020 09:00:00 EEST | Business Wire | Press release

Share

Regulatory News:

Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeutics to address global unmet medical needs, today is pleased to announce that its Class A Ordinary Shares has commenced trading on the Professional Compartment of Euronext in Paris under the Euronext ticker symbol “APM” and ISIN Code: KYG6096M1069. Aptorum Group’s Class A Ordinary Shares continues to be listed on the Nasdaq Global Market under the symbol APM.

The 7,950,986 Class A Ordinary Shares of Aptorum Group got admitted to trading on Euronext market in Paris after Aptorum Group received a visa for its prospectus granted by the French Autorité des Marchés Financiers on 16 July 2020.

Reed Smith LLP acts as Aptorum Group’s legal advisor and listing agent. BNP Paribas Securities Services acts as Aptorum Group’s trading agent.

About Aptorum Group

Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle current unmet medical needs. Aptorum Group’s current drug pipeline includes indications in orphan diseases, infectious diseases and metabolic diseases, a number of which are targeted to enter clinical trial phases. Aptorum Group is also launching a women’s health supplement, dioscorea opposita bioactive nutraceutical tablets marketed under the brand name NativusWell®.

For more information about Aptorum Group, please visit our website: www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future and the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020. As a result, the projections included in such forward-looking statements are subject to change and could be materially different from those described herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This press release is provided ”as is” without any representation or warranty of any kind.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor relations

Aptorum Group limited
Investor Relations Department:
Tel: +852 3953 7700
Email: investor.relations@aptorumgroup.com

Actifin – Financial Communications Europe

Investor relations
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 1 56 88 11 22

Redchip – Financial Communications United States

Investor relations
RedChip Companies, Inc.
dave@redchip.com
+1 407 491 4498

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 16:45:00 EET | Press release

We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live

Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 16:39:00 EET | Press release

Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real capacity. Factbird is a System of Action, built for manufacturers who have plenty of data and struggle to act on it. It connects production data from every line, machine, and operator

Argenta and Loyal Announce Partnership to Advance LOY-003, Loyal's Lifespan-Extension Candidate for Large-Breed Dogs16.11.2026 16:17:00 EET | Press release

Argenta, the global contract development, research and manufacturing organization (CDRMO) dedicated exclusively to animal health, and Loyal, the clinical-stage animal health company pioneering the first lifespan extension drugs for dogs, today announced a strategic partnership under which Argenta will support early-stage development of LOY-003, Loyal's investigational candidate for large-breed dog lifespan extension. The collaboration will focus on early development of the drug, with the potential to expand as the program advances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116891949/en/ Founded by CEO Celine Halioua, Loyal is working to bring the first FDA-approved lifespan extension drugs to market for dogs. The company's pipeline includes three investigational candidates designed to target the underlying biology of canine aging and help dogs live longer, healthier lives alongside the people who love them. LOY-003 i

NIKE, Inc. Unveils the Next Generation of Innovation Across Performance Sports and Sportswear16.11.2026 16:08:00 EET | Press release

NIKE, Inc. (NYSE: NKE) is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261115196647/en/ NIKE, Inc. is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. Elite marathoners. Backyard hoopers. An athlete* walking into the gym for the first time. Every athlete NIKE, Inc. works alongside pushes the company to imagine what doesn’t yet exist, then make those possibilities real. Today, NIKE, Inc. is showing what comes next. As part of its World of Athletes* showcase in Beaverton, Ore., the company is unveiling Tuned Air, the next frontier of Nike Air; new Nike Mind and Nike Free footwear, platforms built to scale across sport; innovation

Cordica Medical Launches PTFE Etched Liners for Interventional Catheter Designs16.11.2026 14:00:00 EET | Press release

Cordica Medical (Cordica), a medical device contract development and manufacturing organization (CDMO), today launched its PTFE Etched Liner portfolio: lubricious ID, bond-ready etched OD PTFE liners for interventional catheter designs, from cardiovascular to neurovascular and more. Standard sizes are available now on the Cordica webstore and ship in 48 hours. Custom sizes are built in 2–3 weeks. The launch coincides with the first day of COMPAMED 2026 in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116876181/en/ Pictured: Cordica’s PTFE Etched Liner. Each liner has a low-friction PTFE inner diameter designed to facilitate device and guidewire passage with a chemically etched outer diameter surface that is designed to enhance bonding to the catheter jacket. The liners are designed to be drawn down over a mandrel for a snug fit and a defined ID before braiding, coiling, and jacketing, and the thin wa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye